Penumbra (NYSE:PEN) EVP Sells $149,820.00 in Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $249.70, for a total value of $149,820.00. Following the completion of the transaction, the executive vice president owned 64,257 shares of the company’s stock, valued at $16,044,972.90. The trade was a 0.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Johanna Roberts also recently made the following trade(s):

• On Tuesday, September 2nd, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $270.58, for a total value of $162,348.00.
• On Monday, August 11th, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $238.94, for a total value of $143,364.00.

Penumbra Trading Up 1.0%

Penumbra stock opened at $256.05 on Friday. Penumbra, Inc. has a 52 week low of $190.08 and a 52 week high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75. The stock has a market capitalization of $9.99 billion, a P/E ratio of 68.10, a PEG ratio of 2.29 and a beta of 0.41. The stock has a 50-day simple moving average of $257.64 and a 200 day simple moving average of $262.97.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.05. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The business had revenue of $339.46 million during the quarter, compared to analysts’ expectations of $327.37 million. During the same quarter last year, the company posted $0.64 earnings per share. Penumbra’s quarterly revenue was up 13.4% on a year-over-year basis. Penumbra has set its FY 2025 guidance at EPS. Analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Institutional Investors Weigh In On Penumbra

Hedge funds and other institutional investors have recently made changes to their positions in the business. Concurrent Investment Advisors LLC acquired a new stake in shares of Penumbra in the first quarter valued at approximately $259,000. GAMMA Investing LLC raised its position in Penumbra by 59.0% during the first quarter. GAMMA Investing LLC now owns 709 shares of the company’s stock valued at $190,000 after purchasing an additional 263 shares in the last quarter. Fortis Capital Advisors LLC acquired a new position in Penumbra during the first quarter valued at approximately $732,000. Belpointe Asset Management LLC acquired a new position in Penumbra during the first quarter valued at approximately $732,000. Finally, Sheets Smith Investment Management acquired a new position in Penumbra during the first quarter valued at approximately $773,000. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PEN. Morgan Stanley lifted their price target on Penumbra from $260.00 to $266.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Wall Street Zen cut Penumbra from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Wells Fargo & Company set a $290.00 price objective on Penumbra in a report on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a report on Saturday, September 27th. Finally, Evercore ISI started coverage on Penumbra in a report on Tuesday, September 2nd. They set an “outperform” rating and a $300.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Penumbra presently has a consensus rating of “Moderate Buy” and an average price target of $302.93.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.